Ampersand Capital Partners logo

Ampersand Capital Partners

North America, Massachusetts, United States, Wellesley

Description

Ampersand is a middle market private equity firm that focuses on healthcare and industrial sectors.

Investor Profile

Ampersand Capital Partners has made 68 investments, with 1 in the past 12 months and 46% as lead.

Stage Focus

  • Private Equity (37%)
  • Series Unknown (28%)
  • Series A (10%)
  • Series B (9%)
  • Series D (4%)
  • Series C (4%)
  • Debt Financing (1%)
  • Post Ipo Equity (1%)
  • Series F (1%)
  • Series E (1%)

Country Focus

  • United States (84%)
  • Germany (4%)
  • The Netherlands (3%)
  • Australia (3%)
  • New Zealand (1%)
  • United Kingdom (1%)
  • Spain (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Manufacturing
  • Medical
  • Pharmaceutical
  • Telecommunications
  • Wireless
  • Software
  • Medical Device
  • Life Science
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Ampersand Capital Partners frequently co-invest with?

Sevin Rosen Funds
North America, Texas, United States, Dallas
Co-Investments: 4
Oak Investment Partners
North America, Connecticut, United States, Wilton
Co-Investments: 3
Diamondhead Ventures
North America, California, United States, Menlo Park
Co-Investments: 4
Nexus Medical Partners
North America, Massachusetts, United States, Quincy
Co-Investments: 2
Benaroya Capital
North America, Washington, United States, Bellevue
Co-Investments: 2
Dynamk Capital
North America, New York, United States, New York
Co-Investments: 2
Charles River Laboratories International
North America, Massachusetts, United States, Wilmington
Co-Investments: 2
New England Partners
North America, Massachusetts, United States, Quincy
Co-Investments: 2
Venrock
North America, California, United States, Palo Alto
Co-Investments: 3
Telecom Partners
North America, New York, United States, New York
Co-Investments: 3

What are some of recent deals done by Ampersand Capital Partners?

VIVEbiotech

San Sebastian, Pais Vasco, Spain

VIVEbiotech is a GMP Contract Development and Manufacturing Organization (CDMO) specialized in Lentiviral vectors.

BiotechnologyManufacturing
Private EquityDec 4, 2024
Julius Clinical

Zeist, Utrecht, The Netherlands

Julius Clinical specializes in distinct therapeutic areas that offer a full-service proposal or separate functional service.

Health CareHospitalPharmaceutical
Private EquityNov 28, 2023
ProtaGene

Heilbronn, Baden-Wurttemberg, Germany

ProtaGene is a CRO partner for the biopharmaceutical, cell, and gene therapy industries.

BiopharmaBiotechnologyTherapeutics
Private EquityNov 20, 2023
Genezen

Indianapolis, Indiana, United States

Genezen offers contract process development, GMP viral vector production, transduced cell manufacturing, and testing services.

BiotechnologyGeneticsManufacturing
Series UnknownNov 2, 2023
Amount Raised: $18,500,000
Vernal Biosciences

Burlington, Vermont, United States

Vernal Biosciences specializes in high-purity mRNA for research and clinical use.

BiotechnologyLife ScienceMedical
Series AJun 27, 2023
Amount Raised: $20,000,000
NanoImaging Services

San Diego, California, United States

NanoImaging Services (NIS) provides cryo-EM imaging services to the pharmaceutical and biotechnology communities.

BiotechnologyNanotechnologyPharmaceutical
Private EquityJun 12, 2023
Sterling Medical Devices

Moonachie, New Jersey, United States

Sterling Medical Devices is a custom electro-mechanical and software solution provider for the medical device industry.

Health CareMedicalMedical Device
Private EquityJun 23, 2022
AnaBios

San Diego, California, United States

AnaBios provides contract research services for biotechnology and pharmaceutical industries.

BiotechnologyMedicalPharmaceutical
Series CJun 7, 2022
Amount Raised: $6,499,999
Vernal Biosciences

Burlington, Vermont, United States

Vernal Biosciences specializes in high-purity mRNA for research and clinical use.

BiotechnologyLife ScienceMedical
Series AJun 2, 2022
Amount Raised: $21,000,000
Syft Technologies

Auckland, Auckland, New Zealand

Syft Technologies designs and manufactures a revolutionary Mass Spectrometer that enables detection of virtually all gaseous chemicals

ManufacturingMarket Research
Private EquityApr 18, 2022